Free tool
FAERS Monitor: Somavert
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 021106 or its brand name (Somavert, Pegvisomant). Reports on generic versions are filed under their own applications.
Reports
4,106
Serious
2,291
56% of reports
Hospitalization
801
Death reported
320
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use491
- drug ineffective438
- headache404
- fatigue387
- insulin-like growth factor increased380
- arthralgia300
- product dose omission issue268
- injection site pain261
- diarrhoea256
- nausea231
- pain213
- blood pressure increased206
- needle issue204
- product use issue203
- malaise201
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 23 |
| 2005 | 35 |
| 2006 | 39 |
| 2007 | 22 |
| 2008 | 23 |
| 2009 | 38 |
| 2010 | 88 |
| 2011 | 73 |
| 2012 | 102 |
| 2013 | 156 |
| 2014 | 164 |
| 2015 | 176 |
| 2016 | 181 |
| 2017 | 276 |
| 2018 | 382 |
| 2019 | 402 |
| 2020 | 354 |
| 2021 | 245 |
| 2022 | 350 |
| 2023 | 455 |
| 2024 | 261 |
| 2025 | 196 |
| 2026 | 65 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,053 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| insulin-like growth factor increasedSignal | 380 | 1860.7 | 1661.3 | 516,887 |
| needle issueSignal | 204 | 36.1 | 31.6 | 6,896 |
| blood pressure increasedSignal | 206 | 6.9 | 6.0 | 1,042 |
| product use issueSignal | 203 | 5.5 | 4.8 | 756 |
| product dose omission issueSignal | 268 | 4.7 | 4.2 | 780 |
| injection site painSignal | 261 | 4.4 | 3.9 | 682 |
| arthralgiaSignal | 300 | 3.7 | 3.3 | 599 |
| headacheSignal | 404 | 3.3 | 3.0 | 666 |
| off label useSignal | 491 | 2.9 | 2.6 | 623 |
| fatigueSignal | 387 | 2.5 | 2.3 | 376 |
| malaiseSignal | 201 | 2.3 | 2.1 | 157 |
| diarrhoeaSignal | 256 | 2.0 | 1.8 | 137 |
| pain | 213 | 1.8 | 1.6 | 74 |
| drug ineffective | 438 | 1.7 | 1.6 | 135 |
| nausea | 231 | 1.5 | 1.3 | 39 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.